BridgeMD
Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphoma
EU CTIS ID: 2024-514122-23-00
What this study is testing
To determine the efficacy of tafasitamab in combination with acalabrutinib in patients with relapsed or refractory MZL
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Ability to understand and willingness to sign a written informed consent
- Adequate kidney and liver function
- Adequate coagulation parameters
- Women with childbearing potential who are using highly effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and for at least 3 months after the last IMP dose
- Men who agree not to father a child during trial treatment and for at least 3 months after the last IMP dose
- Patient able and willing to swallow trial drugs as whole capsule
You likely can't join if
- History of prior malignancy that could affect compliance with the protocol or interpretation of results, except for the following: a. Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the prostate at any time prior to study, b. Other cancers not specified above that have been curatively treated by surgery and/or radiation therapy from which patient is disease-free for ≥3 years without further treatment
- Patients with a history of confirmed progressive multifocal leukoencephalopathy (PML)
- Concomitant diseases that require anticoagulant therapy with warfarin or phenoprocoumon or other vitamin K antagonists and patients treated with dual anti-platelet therapy
- Malabsorption syndrome or other condition that precludes enteral route of administration
- Known hypersensitivity to trial drugs or to any component of the trial drugs
- Concomitant treatment with strong CYP3A inducers or inhibitors
See the full eligibility criteria
Who can join
- Ability to understand and willingness to sign a written informed consent
- Adequate kidney and liver function
- Adequate coagulation parameters
- Women with childbearing potential who are using highly effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and for at least 3 months after the last IMP dose
- Men who agree not to father a child during trial treatment and for at least 3 months after the last IMP dose
- Patient able and willing to swallow trial drugs as whole capsule
- Histologically confirmed diagnosis of MZL
- Disease refractory to or in first or greater relapse after prior systemic therapy
- In need of treatment disease satisfying the following criteria: • EMZL: symptomatic lymphoma or with other treatment indications (overt progression, deep invasion, bulky disease, impending organ damage, patient preference), symptomatic disseminated disease, contraindications to radiotherapy (RT), failure after antibiotics or after local therapy, • SMZL: presence of progressive or symptomatic splenomegaly and/ or any progressive cytopaenias, • NMZL: B symptoms, deterioration of peripheral blood counts due to lymphoma infiltration of the bone marrow, rapid enlargement of lymph nodes or compression of vital organs by bulky disease
- Measurable or non-measurable lesions where the response is nevertheless evaluable by non-imaging means (e.g., gastric or bone marrow infiltrations)
- Ann Arbor Stage I-IV (Appendix A)
- ECOG performance status of 0, 1 or 2 with no deterioration over the previous 2 weeks prior to registration
- Age ≥ 18 years
- Absolute neutrophil count (ANC) ≥ 1.000/mm3 and platelets ≥ 100.000/mm3, unless these abnormalities are related to bone marrow infiltration or to hypersplenism
What rules you out
- History of prior malignancy that could affect compliance with the protocol or interpretation of results, except for the following: a. Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the prostate at any time prior to study, b. Other cancers not specified above that have been curatively treated by surgery and/or radiation therapy from which patient is disease-free for ≥3 years without further treatment
- Patients with a history of confirmed progressive multifocal leukoencephalopathy (PML)
- Concomitant diseases that require anticoagulant therapy with warfarin or phenoprocoumon or other vitamin K antagonists and patients treated with dual anti-platelet therapy
- Malabsorption syndrome or other condition that precludes enteral route of administration
- Known hypersensitivity to trial drugs or to any component of the trial drugs
- Concomitant treatment with strong CYP3A inducers or inhibitors
- Treatment with proton pump inhibitors. Subjects receiving proton pump inhibitors who switch to antacids are eligible for enrollment to this study
- Concurrent participation in another therapeutic clinical trial
- History of or ongoing confirmed central nervous system (CNS) lymphoma
- Patients who received any IMP within 30 days or 5 half-lives (whichever is shorter) before the first dose of the study IMP
- Patients who received a live virus vaccination within 28 days of the first IMP dose
- Any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment
- Pregnant or breastfeeding women
- Active human immunodeficiency virus (HIV) or active chronic hepatitis C or hepatitis B virus infection. Patients positive for hepatitis B core antibody (HBcAb) will be eligible if they are negative for HBV-DNA
- Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy with > 20 mg daily of prednisone dose or equivalent
- Major surgery and any systemic anti-cancer treatment within 3 weeks prior to registration. If patients had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first IMP dose
- Prior exposure to a BTK inhibitor or CD19-targeted therapy
- Steroid therapy for anti-neoplastic intent
- Severe or uncontrolled cardiovascular diseases
- History of cerebrovascular accident or intracranial hemorrhage within 6 months prior to registration and known bleeding disorders (e.g., von Willebrand's disease or hemophilia)
The study team makes the final eligibility decision.
Where it's taking place
- Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.